ESC 365 - Potential for drug-drug interaction between vonoprazan and prasugrel on antiplatelet effect assessed by VerifyNow P2Y12 assay in patients with coronary artery disease

ESC Premium Access

Potential for drug-drug interaction between vonoprazan and prasugrel on antiplatelet effect assessed by VerifyNow P2Y12 assay in patients with coronary artery disease

Session: Poster Session 7 - Acute Coronary Syndromes - Treatment antiplatelet

Topic: Pharmacotherapy

Speaker: Doctor S. Koga (Tokyo, JP)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Doctor Seiji Koga

Juntendo University Nerima Hospital, Tokyo (Japan)

0 follower

9 more presentations in this session

Ischemic and bleeding events during dual antiplatelet therapy after second-generation drug-eluting stent implantation in hemodialysis patients: a propensity score-matched analysis

Speaker: Doctor A. Shimizu (Kitakyushu, JP)

Predictors of bleeding in elderly patients with myocardial infarction: data from the real world

Speaker: Doctor S. Alegria (Almada, PT)

Myocardial infarction with nonobstructive coronary arteries: does aspirin have a place in the treatment of this entity?

Speaker: Doctor J. Ferreira (Coimbra, PT)

Platelet reactivity in Hepatitis C virus infected patients on dual antiplatelet therapy for acute coronary syndrome

Speaker: Doctor F. Scudiero (Seriate, IT)

Potential benefit of ticagrelor monotherapy for patients with hypertension undergoing percutaneous coronary intervention: Insights from the Global Leaders trial

Speaker: Doctor R. Modolo (Maple Grove, US)

Access the full session

Poster Session 7 - Acute Coronary Syndromes - Treatment antiplatelet

Speakers: Doctor S. Koga, Doctor A. Shimizu, Doctor S. Alegria, Doctor J. Ferreira, Doctor F. Scudiero...

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources